Medicines Patent Pool, ViiV Healthcare enter negotiations over voluntary licensing of cabotegravir Long-Acting for HIV pre-exposure prophylaxis

Read More

MPP joins ATOM, a new global coalition to increase access to and the use of essential cancer medicines in low and lower middle-income countries

Read More

WHO and MPP announce agreement with NIH for COVID-19 health technologies

Read More

WHO and MPP announce names of 15 manufactures to receive training from mRNA technology transfer hub

Read More

Bringing medicines closer to those who need them the most

Read More

About Us

The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders, to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.

To date, MPP has signed agreements with 15 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, two long-acting technologies, two experimental oral antiviral treatments for COVID-19 and 12 COVID-19 technologies.

MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC). MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, and SDC.

Featured

mRNA Technology Transfer Hub Programme

12 April 2022

LAPaL

14 February 2022

Access to Medicines Tracker

02 March 2020

VaxPaL

08 June 2021

Discover MedsPaL

MedsPaL, MPP’s medicines patents and licences database, is a free resource that provides information on the intellectual property status of selected patented essential medicines in low- and middle-income countries.

Dive into it today!

"The Medicines Patent Pool was established as a landmark initiative to expand access to treatments for priority diseases. Over the last decade, MPP has become a strong partner in global health, working to facilitate access to HIV and hepatitis C medicines in low- and middle-income countries through voluntary licensing and patent pooling. With its impressive track record, MPP has a critical role to play in making affordable versions of patented essential medicines and technologies available to those who need it the most, including for COVID-19."

Dr Tedros Adhanom Ghebreyesus, Director-General, World Health Organization

"The creation fo the Medicines Patent Pool by Unitaid ten years ago enabled the production of generics that treat tens of millions of people around the world. This led to important successes such as an annual treatment for HIV/AIDS for less than USD 70 in Africa, instead of USD 10,000 in Europe. Today, maybe more than ever, we need MPP’s model to help pharmaceutical companies license their rights on a voluntary basis and continue to save lives."

Marisol Touraine, Chair of the Executive Board of Unitaid

"As the Medicines Patent Pool celebrates its ten-year anniversary, we are proud to support MPP’s effort to speed up access to essential medicines in low- and middle-income countries. MPP’s voluntary licence mechanism is very much needed, especially in times of the COVID-19 pandemic, as it promotes a collaborative vision of ensuring rapid access of quality-assured affordable essential medicines to people living in low- and middle-income countries while acknowledging the need to fund innovation."

Alexander Schulze, Head of the Division Global Programme Health, Federal Department of Foreign Affairs, Swiss Agency for Development and Cooperation

MPP in Numbers

0

patent holders with MPP signed agreements

0

generic manufactures and product developers have sublicenses from MPP

0 Bn
doses of treatment supplied (Jan 2012 - Dec 2020)
US$0 Mn
dollars saved through MPP'S licences (Jan 2012 - Dec 2020)
By 2030
US$0 Bn
projected dollars saved
0
countries have benefited from access to MPP-licensed products
0 Mn
patient-years of treatment through MPPs generic partners (Jan 2012 - Dec 2020)
0
deaths averted (Jan 2012 - Dec 2020)
By 2030
0
deaths averted

For Everyone Everywhere

Discover where we helped and what we have achieved

 

Patent and licensing status: last updated on 11 May 2021. Disclaimer | Product availability data from MPP sublicensees: last updated in March 2022 (data as of 31 December 2021) | Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions

Impact Stories

How access to antiretrovirals is building the future

Dr. Rachel Musoke is a paediatrician who, for the last 15 years, has devoted her care to Nyumbani Children’s Home, a refuge for children living with HIV in Kenya.
Watch more stories!

Additional Tools

Business Model

Prioritising Medicines for Licensing

Licences

MedsPaL

Key Publications

Related Publications

Shaping the global innovation and access landscape for better paediatric medicines – GAP-f 2022-2024 strategy

01 March 2022

Related Publications

Pediatric COVID-19 Therapeutics: Seizing the Right Research and Development Opportunities to Accelerate Access for Children

17 January 2022

Annual Reports

2020 Annual Report: A Decade of Making Medicines Accessible

15 July 2021

Contact Us

Business Development

Queries from originators and generic manufacturers

Legal

Information about our licence agreements

MedsPaL

Information about our medicines patents and licences database

Policy and Advocacy

Communication from countries and organisations

Press and Media

Strategy, Operations and Resource Mobilisation

MPP Logo

Subscribe to our Newsletter

About Us
Licences
MedsPaL
Careers & RFPs
Contact

Founded & funded by

Unitaid Logo

Other funders